The company's product Hemopure (HBOC-201) has been featured in a number of scientific articles in the past few months, among them are the following:
2. Br J Hosp Med (Lond). Njoku M1, Peter DS, Mackenzie CF. 2015 Feb;76(2):78-83. doi: 10.12968/hmed.2015.76.2.78.
Haemoglobin-based oxygen carriers: indications and future applications.
· Associate Professor in the Department of Anesthesiology, Department of Anesthesiology, Shock Trauma Anesthesiology Research Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
This article describes current oxygen-carrying solutions, four new products and new indications to increase the benefit/risk ratio of haemoglobin-basedoxygen carriers compared to blood. Indications include when blood is not available, if blood is contaminated, is refused or contraindicated, and for organ preservation.
3. Am J Ther. 2014 Oct 3.
Are Hemoglobin-Based Oxygen Carriers Being Withheld Because of Regulatory Requirement for Equivalence to Packed Red Blood Cells?
Mackenzie CF1, Pitman AN, Hodgson RE, Sussman MJ, Levien LJ, Jahr JS, Greenburg AG.
· University of Maryland School of Medicine, Baltimore, MD; 2OPK Biotech LLC, Cambridge, MA; 3Inkosi Albert Luthuli Central Hospital and Nelson R. Mandela School of Medicine, Department of Anesthesia and Pain Management, Durban, South Africa; 4Milpark Clinic, Department of Surgery, Johannesburg, South Africa; 5Sunninghill Hospital, Department of Surgery, Johannesburg, South Africa; 6David Geffen School of Medicine, Department of Anesthsiology, University of California, Los Angeles, Los Angeles, CA; and 7Brown University School of Medicine, Department of Surgery, Providence, RI.
4. Int J Burns Trauma. Lundy JB1, Lewis CJ1, Cancio LC1, Cap AP1. 2014 Feb 22;4(1):45-8. eCollection 2014.
Experience with the use of Hemopure in the care of a massively burned adult.
· U.S. Army Institute of Surgical Research Fort Sam Houston, TX, USA.
To report the use of a bovine hemoglobin-based oxygen carrier (HBOC-201) in an elderly patient sustaining extensive thermal injury unable to receive allogenic transfusion due to religious preference.
Case report and literature review describing steps required for acquisition and safe infusion of HBOC-201.
Six units of HBOC-201 were infused in the perioperative period for anemia with signs of critically low oxygen delivery without adverse sequelae. The patient ultimately died as a result of multiple organ failure.
Despite disappointing results of the use of HBOCs in other patient populations, there is a role for compassionate, emergency use of cell-free hemoglobin in the management of burn patients unable to receive allogenic blood products.
5. Anesth Analg. Weiskopf RB1. 2014 Oct;119(4):758-60. doi: 10.1213/ANE.0000000000000401.
Hemoglobin-based oxygen carriers: disclosed history and the way ahead: the relativity of safety.
· From the Department of Anesthesia, University of California, San Francisco, California.
· A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter red blood cell controlled trial in noncardiac surgery patients. [Anesth Analg. 2014]
6. Anesth Analg. Van Hemelrijck J1, Levien LJ, Veeckman L, Pitman A, Zafirelis Z, Standl T. 2014 Oct;119(4):766-76. doi: 10.1213/ANE.0000000000000305.
A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter redblood cell controlled trial in noncardiac surgery patients.
We present the results of a previously unpublished hemoglobin-based oxygen carrier (HBOC) study conducted in 1998-1999.
In a multicenter, randomized, single-blind, comparative study of HBOC-201 versus allogeneic red blood cell (RBC) transfusions, no-cardiac surgery patients received HBOC-201 to a maximum of 7 units (n = 83) or RBCs (n = 77). Patients could be switched to RBCs for safety or any other reason. The efficacy end points were elimination and/or reduction of allogeneic RBC transfusions for 28 days.
The proportion of patients in the HBOC-201 group that avoided RBC transfusion was 0.427 (95% confidence interval, 0.321-0.533). Subjects in the HBOC-201 group received on average 3.2 units of RBCs versus 4.4 units in the control arm (P = 0.004). Seventy-nine (95.2%) subjects in the HBOC-201 group and 72 (93.5%) in the RBC group experienced adverse events (AEs), judged to be associated with study treatment in 59 (71.1%) and 18 (23.4%) subjects, respectively. Thirty-day mortality, 5 (6.0%) vs 4 (5.2%) patients (P = 1.00), incidence of serious AEs, 24 (28.9%) vs 20 (26.0%) (P = 0.73), or time to intensive care unit (log-rank P = 0.15) or hospital discharge (log-rank P = 0.53) were similar for theHBOC-201 and RBC groups, respectively.
Up to 7 units of HBOC-201 infused over the course of 6 days resulted in RBC transfusion avoidance in 43% of patients. There were no notable differences in mortality and serious AEs incidence. The use of HBOC-201 was associated with a notable excess of nonserious AEs.
Press Coverage: Wildlife Aid Foundation releases video of Anaemic baby badger saved from near-death by Oxyglobin
HbO2 Therapeutics LLC has acquired the assets of OPK Biotech LLC, including the manufacturing facility and intellectual property. The Company will now be headquartered 35 miles north of Philadelphia in Souderton, Pennsylvania.
HbO2 Therapeutics LLC - All Rights Reserved